Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Current standard values of health utility scores for evaluating cost-effectiveness in liver disease: A meta-analysis
Tomohiro Ishinuki, Shigenori Ota, Kohei Harada, Masaki Kawamoto, Makoto Meguro, Goro Kutomi, Hiroomi Tatsumi, Keisuke Harada, Koji Miyanishi, Toru Kato, Toshio Ohyanagi, Thomas T Hui, Toru Mizuguchi
Tomohiro Ishinuki, Toru Mizuguchi, Department of Nursing, Surgical Sciences, Sapporo Medical University, Sapporo 0608556, Japan
Shigenori Ota, Goro Kutomi, Toru Kato, Departments of Surgery, Surgical Science and Oncology, Sapporo Medical University, Sapporo 0608543, Japan
Kohei Harada, Department of Radiology, Sapporo Medical University, Sapporo 0608543, Japan
Masaki Kawamoto, Departments of Surgery, Nemuro City Hospital, Nemuro 0870008, Japan
Makoto Meguro, Departments of Surgery, Sapporo Satozuka Hospital, Sapporo 0040811, Japan
Hiroomi Tatsumi, Department of Intensive Care Medicine, Sapporo Medical University, Sapporo 0608543, Japan
Keisuke Harada, Department of Emergency Medicine, Sapporo Medical University, Sapporo 0608543, Japan
Koji Miyanishi, Department of Medical Oncology, Sapporo Medical University, Sapporo 0608543, Japan
Toshio Ohyanagi, Department of Liberal Arts and Sciences, Center for Medical Education, Sapporo Medical University, Sapporo 0608556, Japan
Thomas T Hui, Departments of Surgery, Stanford University School of Medicine, Stanford, 94598, United States
Author contributions: Ishinuki T and Ota S conceptualized and designed the review; Ishinuki T, Harada K, Kawamoto M, and Meguro M searched for and screened the articles; Kutomi G, Tatsumi H, Harada K, and Kato T assessed the articles for eligibility; Miyanishi K and Ohyanagi T carried out the statistical analyses; Hui TT and Mizuguchi T drafted the initial manuscript; Mizuguchi T finalized the manuscript; and all of the authors reviewed and approved the final manuscript as submitted.
Supported by Grants-in-Aid from JSPS KAKENHI, No. JP 20K10404 (to Mizuguchi T) and No. JP 21K10715 (to Ishinuki T); the Hokkaido Hepatitis B Litigation Orange Fund, No. 2059198 (to Mizuguchi T) and No. 2136589 (to Harada K); Terumo Life Science Foundation, No. 2000666; Pfizer Health Research Foundation, No. 2000777; the Viral Hepatitis Research Foundation of Japan, No. 3039838; Project Mirai Cancer Research Grants, No. 202110251; Takahashi Industrial and Economic Research Foundation, No. 12-003-106; Daiichi Sankyo Company, No. 2109540; Shionogi and Co., No. 2109493; MSD, No. 2099412; Takeda Pharmaceutical Company, No. 2000555; Sapporo Doto Hospital, No. 2039118; Noguchi Hospital, No. 2029083; Doki-kai Tomakomai Hospital, No. 2059203; Tsuchida Hospital, No. 2000092; Shinyu-kai Noguchi Hospital, No. 2029083 (to Mizuguchi T); and the Yasuda Medical Foundation, No. 28-1 (to Ishinuki T).
Conflict-of-interest statement: All authors have nothing to disclose.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist statement, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Toru Mizuguchi, MD, PhD, Professor, Department of Nursing, Surgical Sciences, Sapporo Medical University, S1, W17, Chuo-ku, Sapporo 0608556, Japan. tmizu@sapmed.ac.jp
Received: January 13, 2022
Peer-review started: January 13, 2022
First decision: April 16, 2022
Revised: April 26, 2022
Accepted: July 24, 2022
Article in press: July 24, 2022
Published online: August 21, 2022
BACKGROUND
Health utility assessments have been developed for various conditions, including chronic liver disease. Health utility scores are required for socio-economic evaluations, which can aid the distribution of national budgets. However, the standard health utility assessment scores for specific health conditions are largely unknown.
AIM
To summarize the health utility scores, including the EuroQOL 5-dimensions 5-levels (EQ-5D-5L), EuroQol-visual analogue scale, short from-36 (SF-36), RAND-36, and Health Utilities Index (HUI)-Mark2/Mark3 scores, for the normal population and chronic liver disease patients.
METHODS
A systematic literature search of PubMed and MEDLINE, including the Cochrane Library, was performed. Meta-analysis was performed using the RevMan software. Multiple means and standard deviations were combined using the StatsToDo online web program.
RESULTS
The EQ-5D-5L and SF-36 can be used for health utility evaluations during antiviral therapy for hepatitis C. HUI-Mark2/Mark3 indicated that the health utility scores of hepatitis B patients are roughly 30% better than those of hepatitis C patients.
CONCLUSION
The EQ-5D-5L is the most popular questionnaire for health utility assessments. Health assessments that allow free registration would be useful for evaluating health utility in patients with liver disease.
Core Tip: This study summarized current knowledge about health utility assessments, including the EuroQOL 5-dimensions 5-levels (EQ-5D-5L), EuroQol-visual analogue scale, short from-36, RAND-36, and Health Utilities Index-Mark2/Mark3. The EQ-5D-5L is the most popular questionnaire for health utility assessments. Health utility assessments need to be used widely and routinely.
